Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008

Tuesday, November 11, 2008 General News J E 4
PALO ALTO, Calif., Nov. 10 Jazz Pharmaceuticals,Inc. (Nasdaq: JAZZ) today announced that it will report third quarter 2008financial results on November 13, 2008, before the open of U.S. financialmarkets. Jazz Pharmaceuticals will host an investor conference call and liveaudio webcast to discuss the results and company updates on November 13, 2008,at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time.

The live webcast and press release may be accessed on JazzPharmaceuticals' website at Pleaseconnect to the website prior to the start of the conference call to ensureadequate time for any software downloads that may be necessary to listen tothe webcast. An archived version of the webcast will be available throughNovember 27, 2008.

Investors may participate in the conference call by dialing 866-825-3308in the U.S., or 617-213-8062 outside the U.S., and entering passcode 82730571.A replay of this call will be available until November 27, 2008 at888-286-8010 or 617-801-6888 (international), using the passcode 10707678.

The webcast is also being distributed through the Thomson StreetEventsNetwork to both institutional and individual investors. Individual investorscan listen to the call at and institutional investorscan access the call via

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company identifying,developing and commercializing innovative treatments for important,underserved markets in neurology and psychiatry. For further information,please visit

SOURCE Jazz Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Hill-Rom Reports Fourth Quarter Revenue Growth of ...
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical ...